Romidepsin

CAS : 128517-07-7

Ref. TR-R425060

Informations sur le produit

• Nom: Romidepsin
• Synonymes: Cyclo[(2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl], cyclic (3->5)-disulfide, L-Valine, N-(3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(Z)-2,3-didehydro-2-aminobutanoyl-, (4->1)-lactone, cyclic (1->2)-disulfide, [S-(E)]-, 2-Oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricosane, cyclic peptide deriv., Antibiotic FR 901228, Chromadax, FK 228, FR 901228, Istodax, NSC 630176, Fr 901228, (1R,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone

Description

Applications Romidepsin is a histone deacetylase inhibitor that can alter chromatin structure and gene transcription leading to multiple changes in cellular protein production. This may result in cell cycle arrest and tumor growth inhibition. Romidepsin has shown anti-proliferative activity in vitro against multiple mouse and human tumor cell lines and in vivo in human tumor xenograft models. Romidepsin can be administered with a second agent, such as a cytotoxic agent, a steroidal agent, a proteasome inhibitor, or a kinase inhibitor.
References Ueda, H., et al.: J. Antibiot., 47, 301 (1994), Weidle, U., et al.: Anticancer Res., 20, 1471 (2000), Kitazono, M., et al.: Cancer Res., 61, 6328 (2001), Sandor, V., et al.: Clin. Cancer Res., 8, 718 (2002),

• Marque: TRC

Propriétés chimiques

• Masse moléculaire: 540.70
• Formule: C₂₄H₃₆N₄O₆S₂
• Couleur/Forme: Neat
• InChI: InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1
• Code InChI: InChIKey=OHRURASPPZQGQM-QDBHDZETSA-N
• SMILES: C/C=C1\NC(=O)[C@H]2CSSCCC=C[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O